Testosterone topical - Ferring Pharmaceuticals

Drug Profile

Testosterone topical - Ferring Pharmaceuticals

Alternative Names: FE-999303; Testavan; Testavance

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Hypogonadism

Most Recent Events

  • 23 Mar 2018 Testosterone topical is still in phase III trials for Hypogonadism in USA
  • 15 Mar 2018 Preregistration (Decentralised Procedure) for Hypogonadism in United Kingdom, Sweden, Spain, Slovenia, Slovakia, Romania, Portugal, Poland, Netherlands, Norway, Malta, Luxembourg, Liechtenstein, Lithuania, Latvia, Latvia, Iceland, Italy, Ireland, Hungary, Greece, Germany, France, Finland, Estonia, Denmark, Czech Republic, Cyprus, Croatia, Bulgaria, Belgium, Austria (Topical)
  • 15 Mar 2018 Ferring announces positive outcome of Decentralised Procedure (DCP) for testosterone topical gel in European Union, Iceland, Norway, and Liechtenstein for Hypogonadism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top